Trial Profile

A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic And/or Progressive Metastases

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Pembrolizumab (Primary) ; Yttrium-90 (Primary)
Indications Liver metastases; Neuroendocrine tumours
Focus Adverse reactions; Therapeutic Use

11 Mar 2025 Planned End Date changed from 31 May 2026 to 31 Dec 2026.
11 Mar 2025 Planned primary completion date changed from 31 May 2024 to 31 Dec 2025.
15 Nov 2023 Planned End Date changed from 31 Dec 2025 to 31 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com